ULBP1, human recombinant protein
NKG2D ligand 1, UL16 binding protein 1, RAET1I, N2DL-1, N2DL1, NKG2D ligand 1
|Calculated MW||25 kDa (216 aa, 26-216 aa + His Tag), confirmed by MALDI-TOF.|
|Other Names||NKG2D ligand 1, UL16 binding protein 1, RAET1I, N2DL-1, N2DL1, NKG2D ligand 1|
|Sequence||MGSSHHHHHH SSGLVPRGSH MGSHM GWVDT HCLCYDFIIT PKSRPEPQWC EVQGLVDERP FLHYDCVNHK AKAFASLGKK VNVTKTWEEQ TETLRDVVDF LKGQLLDIQV ENLIPIEPLT LQARMSCEHE AHGHGRGSWQ FLFNGQKFLL FDSNNRKWTA LHPGAKKMTE KWEKNRDVTM FFQKISLGDC KMWLEEFLMY WEQMLDPTKP PSLAPG|
|Storage||-80°C; 0.5 mg/ml in 20 mM Tris-HCl buffer (pH 8.0) containing 0.15 M NaCl, 30% glycerol and 1 mM DTT.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
ULBP1 is ligand for the NKG2D receptor, together with at least ULBP2 and ULBP3. ULBPs activate multiple signaling pathways in primary NK cells, resulting in the production of cytokines and chemokines. In CMV infected cells, ULBP1 interacts with soluble CMV glycoprotein UL16. The interaction with UL16 blocked the interaction with the NKG2D receptor, providing a mechanism by which CMV infected cells might escape the immune system. UL16 also causes ULBP1 to be retained in the ER and cis-Golgi apparatus so that it does not reach the cell surface. Recombinant human ULBP1 protein, fused to His-tag at N-terminus, was expressed in E.coli and purified by using conventional chromatography techniques.
Cosman D.,et al.Immunity 14:123-133(2001).
Onda H.,et al.Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
Radosavljevic M.,et al.Genomics 79:114-123(2002).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Mungall A.J.,et al.Nature 425:805-811(2003).
If you have any additional inquiries please email technical services at email@example.com.